




Instance: composition-en-a0179b039da107bd55842f5819aa0ee7
InstanceOf: CompositionUvEpi
Title: "Composition for ebixa Package Leaflet"
Description:  "Composition for ebixa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/02/219/001-003"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa0179b039da107bd55842f5819aa0ee7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ebixa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Ebixa is and what it is used for </li>
<li>What you need to know before you take Ebixa </li>
<li>How to take Ebixa </li>
<li>Possible side effects </li>
<li>How to store Ebixa </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ebixa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ebixa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ebixa contains the active substance memantine hydrochloride. It belongs to a group of medicines 
known as anti-dementia medicines. 
Memory loss in Alzheimer s disease is due to a disturbance of message signals in the brain. The brain 
contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve 
signals important in learning and memory. Ebixa belongs to a group of medicines called NMDA-
receptor antagonists. Ebixa acts on these NMDA-receptors improving the transmission of nerve 
signals and the memory. </p>
<p>Ebixa is used for the treatment of patients with moderate to severe Alzheimer s disease. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ebixa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ebixa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Ebixa </p>
<ul>
<li>if you are allergic to memantine or any of the other ingredients of this medicine (listed in 
section 6).  </li>
</ul>
<p>Warning and precautions </p>
<p>Talk to your doctor or pharmacist before taking Ebixa:</p>
<ul>
<li>if you have a history of epileptic seizures </li>
<li>if you have recently experienced a myocardial infarction (heart attack), or if you are suffering 
from congestive heart failure or from an uncontrolled hypertension (high blood pressure). </li>
</ul>
<p>In these situations the treatment should be carefully supervised, and the clinical benefit of Ebixa 
reassessed by your doctor on a regular basis. </p>
<p>If you suffer from renal impairment (kidney problems), your doctor should closely monitor your 
kidney function and if necessary adapt the memantine doses accordingly.  </p>
<p>If you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances 
in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract 
(structure that carries urine), your doctor may need to adjust the dose of your medicine. </p>
<p>The use of medicinal products called amantadine (for the treatment of Parkinson s disease), ketamine 
(a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and 
other NMDA-antagonists at the same time should be avoided. </p>
<p>Children and adolescents </p>
<p>Ebixa is not recommended for children and adolescents under the age of 18 years. </p>
<p>Other medicines and Ebixa </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, Ebixa may change the effects of the following medicines and their dose may need to be 
adjusted by your doctor:</p>
<ul>
<li>amantadine, ketamine, dextromethorphan </li>
<li>dantrolene, baclofen </li>
<li>cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine </li>
<li>hydrochlorothiazide (or any combination with hydrochlorothiazide) </li>
<li>anticholinergics (substances generally used to treat movement disorders or intestinal cramps) </li>
<li>anticonvulsants (substances used to prevent and relieve seizures) </li>
<li>barbiturates (substances generally used to induce sleep) </li>
<li>dopaminergic agonists (substances such as L-dopa, bromocriptine) </li>
<li>neuroleptics (substances used in the treatment of mental disorders) </li>
<li>oral anticoagulants </li>
</ul>
<p>If you go into hospital, let your doctor know that you are taking Ebixa. </p>
<p>Ebixa with food and drink </p>
<p>You should inform your doctor if you have recently changed or intend to change your diet 
substantially (e.g. from normal diet to strict vegetarian diet), as your doctor may need to adjust the 
dose of your medicine. </p>
<p>Pregnancy and breast-feeding </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby,<br />
ask your doctor or pharmacist for advice before taking this medicine. </p>
<p>Pregnancy </p>
<p>The use of memantine in pregnant women is not recommended.  </p>
<p>Breast-feeding </p>
<p>Women taking Ebixa should not breast-feed. </p>
<p>Driving and using machines </p>
<p>Your doctor will tell you whether your illness allows you to drive and to use machines safely. 
Also, Ebixa may change your reactivity, making driving or operating machinery inappropriate.  </p>
<p>Ebixa contains Sodium </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ebixa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ebixa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take Ebixa exactly as your doctor has told you. Check with your doctor or pharmacist if you 
are not sure. </p>
<p>The recommended dose of Ebixa for adults and older people is 20 mg once a day. In order to reduce 
the risk of side effects this dose is achieved gradually by the following daily treatment scheme: </p>
<p>week 1 </p>
<p>half a 10 mg tablet </p>
<p>week 2 </p>
<p>one 10 mg tablet </p>
<p>week 3 </p>
<p>one and a half 10 mg 
tablets </p>
<p>week 4<br />
and beyond 
two 10 mg tablets once a 
day </p>
<p>The usual starting dose is half a tablet once a day (1x 5 mg) for the first week. This is increased to one 
tablet once a day (1x 10 mg) in the second week and to 1 and a half tablets once a day in the third 
week. From the fourth week on, the usual dose is 2 tablets once a day (1x 20 mg). </p>
<p>Dosage in patients with impaired kidney function </p>
<p>If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In 
this case, monitoring of your kidney function should be performed by your doctor at specified 
intervals. </p>
<p>Administration </p>
<p>Ebixa should be administered orally once a day. To benefit from your medicine you should take it 
regularly every day at the same time of the day. The tablets should be swallowed with some water. 
The tablets can be taken with or without food. </p>
<p>Duration of treatment </p>
<p>Continue to take Ebixa as long as it is of benefit to you. Your doctor should assess your treatment on a 
regular basis.  </p>
<p>If you take more Ebixa than you should </p>
<ul>
<li>In general, taking too much Ebixa should not result in any harm to you. You may experience 
increased symptoms as described in section 4.  Possible side effects .  </li>
<li>If you take a large overdose of Ebixa, contact your doctor or get medical advice, as you may 
need medical attention.  </li>
</ul>
<p>If you forget to take Ebixa </p>
<ul>
<li>If you find you have forgotten to take your dose of Ebixa, wait and take your next dose at the 
usual time.  </li>
<li>Do not take a double dose to make up for a forgotten dose. </li>
</ul>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>In general, the observed side effects are mild to moderate.  </p>
<p>Common (affects 1 to 10 users in 100):<br />
* Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, 
shortness of breath, high blood pressure and drug hypersensitivity </p>
<p>Uncommon (affects 1 to 10 users in 1,000): 
  Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure 
and venous blood clotting (thrombosis/thromboembolism)  </p>
<p>Very Rare (affects less than 1 user in 10,000): 
* Seizures </p>
<p>Not known (frequency cannot be estimated from the available data): 
* Inflammation of the pancreas, inflammation of the liver (hepatitis)  and psychotic reactions </p>
<p>Alzheimer s disease has been associated with depression, suicidal ideation and suicide. These events 
have been reported in patients treated with Ebixa. </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacis. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ebixa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ebixa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month.  </p>
<p>This medicinal product does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Ebixa contains </p>
<ul>
<li>
<p>The active substance is memantine hydrochloride. Each film-coated tablet contains 10 mg 
memantine hydrochloride equivalent to 8.31 mg memantine. </p>
</li>
<li>
<p>The other ingredients are microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous 
silica and magnesium stearate, all in the tablet core; and hypromellose, macrogol 400, titanium 
dioxide (E171) and iron oxide yellow (E172), all in the tablet coating. </p>
</li>
</ul>
<p>What Ebixa looks like and contents of the pack </p>
<p>Ebixa film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with 
breaking line and engravings  1 0  on one side and  M M  on the other side. The tablet can be divided 
into equal doses. </p>
<p>Ebixa film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 30 tablets, 42 tablets, 
49 x 1 tablets, 50 tablets, 56 tablets, 56 x 1 tablets, 70 tablets, 84 tablets, 98 tablets, 98 x 1 tablets, tablets, 100 x 1 tablets, 112 tablets, 980 (10 x 98) tablets or 1000 (20 x 50) tablets. The pack sizes 49 x 
1, 56 x 1, 98 x 1 and 100 x 1 film-coated tablets are presented in unit dose blister. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>H. Lundbeck A/S 
Ottiliavej 9 
2500 Valby 
Denmark. </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgique/Belgi /Belgien 
Lundbeck S.A./N.V. 
T l/Tel: +32 2 535 7Lietuva 
H. Lundbeck A/S, Danija 
Tel: + 45 36301<br />
Lundbeck Export A/S Representative Office 
Tel: +359 2 962 4Luxembourg/Luxemburg 
Lundbeck S.A. 
T l: +32 2 535 7 esk  republika<br />
Lundbeck  esk  republika s.r.o. 
Tel: +420 225 275 Magyarorsz g 
Lundbeck Hungaria Kft. 
Tel: +36 1 4369Danmark 
Lundbeck Pharma A/S 
Tlf: +45 4371 4Malta 
H. Lundbeck A/S, Denmark 
Tel: + 45 36301Deutschland 
Lundbeck GmbH 
Tel: +49 40 23649 0 
Nederland 
Lundbeck B.V. 
Tel: +31 20 697 1Eesti 
Lundbeck Eesti AS 
Tel: + 372 605 9Norge 
H. Lundbeck AS<br />
Tlf: +47 91 300 <br />
Lundbeck Hellas S.A. 
 : +30 210 610 5 sterreich 
Lundbeck Austria GmbH 
Tel: +43 1 253 621 6Espa a 
Lundbeck Espa a S.A. 
Tel: +34 93 494 9Polska 
Lundbeck Poland Sp. z o. o.<br />
Tel.: + 48 22 626 93 France 
Lundbeck SAS 
T l: + 33 1 79 41 29 Portugal 
Lundbeck Portugal Lda 
Tel: +351 21 00 45 Hrvatska 
Lundbeck Croatia d.o.o. 
Tel.: + 385 1 6448Ireland 
Lundbeck (Ireland) Limited 
Tel: +353 1  468 9Rom nia 
Lundbeck Romania SRL 
Tel: +40 21319 88 Slovenija 
Lundbeck Pharma d.o.o. 
Tel.: +386 2 229 4 sland 
Vistor hf. 
Tel: +354 535 7Slovensk  republika 
Lundbeck Slovensko s.r.o. 
Tel: +421 2 5341 42 Italia 
Lundbeck Italia S.p.A. 
Tel: +39 02 677 4Suomi/Finland 
Oy H. Lundbeck Ab 
Puh/Tel: +358 2 276 5<br />
Lundbeck Hellas  A.E 
 .: +357 22490Sverige 
H. Lundbeck AB 
Tel: +46 4069 98Latvija 
H. Lundbeck A/S, D nija 
Tel: + 45 36301United Kingdom (Northern Ireland) 
Lundbeck (Ireland) Limited 
Tel:  +353 1 468 9This leaflet was last approved in MM/YYYY </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-a0179b039da107bd55842f5819aa0ee7
InstanceOf: CompositionUvEpi
Title: "Composition for ebixa Package Leaflet"
Description:  "Composition for ebixa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/02/219/001-003"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa0179b039da107bd55842f5819aa0ee7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - ebixa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal De vide, før De begynder at tage Ebixa </li>
<li>Sådan skal De tage Ebixa </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What ebixa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What ebixa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ebixa indeholder det aktive stof memantinhydrochlorid. Det tilhører gruppen af medicin kaldet 
antidemensmedicin (medicin til behandling af demens). </p>
<p>Hukommelsestab ved Alzheimers sygdom skyldes en forstyrrelse af signalstoffer i hjernen. Hjernen 
indeholder såkaldte N-methyl-D-aspartat (NMDA)-receptorer, der er involveret i overførslen af 
nervesignaler, som er vigtige for indlæring og hukommelse. Ebixa hører til en gruppe af lægemidler 
kaldet NMDA-receptor-antagonister. Ebixa indvirker på disse NMDA-receptorer og forbedrer 
overførslen af nervesignaler samt hukommelsen. </p>
<p>Ebixa anvendes til behandling af patienter med moderat til svær Alzheimers sygdom. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take ebixa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take ebixa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Ebixa </p>
<ul>
<li>hvis De er allergisk over for memantin eller et af de øvrige indholdsstoffer i Ebixa (angivet i 
punkt 6) </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller apotekspersonalet, før De tager Ebixa:</p>
<ul>
<li>hvis De tidligere har haft epileptiske anfald </li>
<li>hvis De for nylig har haft blodprop i hjertet (myokardieinfarkt), eller hvis De lider af dårligt 
hjerte eller ukontrolleret forhøjet blodtryk (hypertension) </li>
</ul>
<p>I disse situationer bør behandlingen overvåges nøje, og den kliniske gavn af Ebixa skal regelmæssigt 
vurderes af Deres læge. </p>
<p>Hvis De har nedsat nyrefunktion (nyreproblemer), bør Deres læge nøje overvåge Deres nyrefunktion 
og om nødvendigt tilpasse memantin-dosen derefter.  </p>
<p>De bør også informere Deres læge, hvis De lider af tilstande med renal tubulær acidose (RTA, 
overskud af syredannende stoffer i blodet på grund af nedsat nyrefunktion) eller alvorlige infektioner i 
urinvejene (som urinen udskilles igennem). Deres læge kan i så fald være nødt til at justere Deres 
medicindosis. </p>
<p>Samtidig brug af lægemidler ved navn amantadin (til behandling af Parkinsons sygdom), ketamin (et 
middel, der anvendes til bedøvelse), dextromethorfan (anvendes generelt til behandling af hoste) og 
andre NMDA-antagonister bør undgås. </p>
<p>Børn og unge </p>
<p>Ebixa anbefales ikke til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Ebixa </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for 
nylig.  </p>
<p>I særdeleshed kan Ebixa ændre virkningen af følgende lægemidler, og lægen kan derfor være nødt til 
at ændre doseringen:</p>
<ul>
<li>amantadin, ketamin, dextromethorfan  </li>
<li>dantrolen, baklofen </li>
<li>cimetidin, ranitidin, procainamid, quinidin, quinin, nikotin </li>
<li>hydrochlorothiazid (eller en hvilken som helst kombination med hydrochlorothiazid) </li>
<li>antikolinergika (stoffer, der generelt bruges til behandling af lidelser i bevægeapparatet eller 
tarmkramper) </li>
<li>antikonvulsiva (stoffer, der bruges til at forebygge og afhjælpe krampeanfald) </li>
<li>barbiturater (stoffer, der generelt bruges som sovemidler) </li>
<li>dopaminerge agonister (stoffer såsom L-dopa, bromokriptin) </li>
<li>neuroleptika (stoffer, der bruges til behandling af sindslidelser) </li>
<li>orale antikoagulantia  </li>
</ul>
<p>Hvis De kommer på hospitalet, skal De sige til lægen, at De får Ebixa. </p>
<p>Brug af Ebixa sammen med mad og drikke </p>
<p>De bør informere Deres læge, hvis De for nylig har ændret eller har i sinde at ændre Deres kost 
væsentligt (f.eks. fra en normal kost til en streng vegetarisk kost). Deres læge kan i så fald være nødt 
til at justere Deres medicindosis. </p>
<p>Graviditet og amning </p>
<p>Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Graviditet </p>
<p>Memantin anbefales ikke til gravide kvinder.  </p>
<p>Amning </p>
<p>Kvinder, der tager Ebixa, bør ikke amme. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Deres læge vil fortælle Dem, om Deres sygdom tillader, at De uden risiko kan køre bil eller 
motorcykel, og om De kan cykle eller arbejde med værktøj og maskiner. Ebixa kan måske også 
påvirke Deres reaktionsevne, så det ikke er hensigtsmæssigt at køre bil, motorcykel eller cykel eller 
arbejde med værktøj og maskiner.  </p>
<p>Ebixa indeholder natrium </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take ebixa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take ebixa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid Ebixa nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller på apoteket.   </p>
<p>Den anbefalede dosis af Ebixa til voksne og til ældre mennesker er 20 mg én gang dagligt. For at 
mindske risikoen for bivirkninger opnås denne dosis gradvist ud fra følgende daglige 
behandlingsskema: </p>
<ol>
<li>uge </li>
</ol>
<p>En halv tablet à 10 mg </p>
<ol>
<li>uge </li>
</ol>
<p>En tablet à 10 mg </p>
<ol>
<li>uge </li>
</ol>
<p>Halvanden tablet à 10 mg </p>
<ol>
<li>uge og derefter 
To tabletter à 10 mg<br />
én gang dagligt  </li>
</ol>
<p>Den normale startdosis er en halv tablet en gang dagligt (1 x 5 mg) i den første uge. Denne øges til en 
tablet en gang dagligt (1 x 10 mg) i den anden uge og til 1½ tablet en gang dagligt i den tredje uge. Fra 
og med den fjerde uge er den normale dosis 2 tabletter en gang dagligt (1 x 20 mg). </p>
<p>Dosis til patienter med nedsat nyrefunktion </p>
<p>Hvis De har nedsat nyrefunktion, afgør Deres læge, hvilken dosis der passer til Deres tilstand. I så fald 
bør Deres læge overvåge Deres nyrefunktion regelmæssigt. </p>
<p>Administration </p>
<p>Ebixa bør indtages gennem munden en gang pr. dag. De bør tage tabletterne regelmæssigt hver dag på 
samme tidspunkt af dagen for at opnå størst mulig virkning af tabletterne. Tabletterne bør synkes 
sammen med noget vand. Tabletterne kan indtages uafhængigt af måltider. </p>
<p>Behandlingens varighed </p>
<p>Bliv ved med at tage Ebixa, så længe De har gavn af det. Deres læge bør regelmæssigt vurdere Deres 
behandling.  </p>
<p>Hvis De har taget for meget Ebixa </p>
<ul>
<li>Generelt burde indtagelse af for meget Ebixa ikke være skadeligt for Dem. De kan opleve 
forøgede symptomer, som beskrevet i punkt 4 “Bivirkninger".  </li>
<li>Hvis De tager en stor overdosis af Ebixa, skal De søge læge, da De kan have behov for 
medicinsk behandling. </li>
</ul>
<p>Hvis De har glemt at tage Ebixa </p>
<ul>
<li>Hvis De har glemt at tage Deres dosis af Ebixa, skal De vente og tage Deres næste dosis på det 
sædvanlige tidspunkt.  </li>
<li>De må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </li>
</ul>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De bivirkninger, der er set, er generelt milde til moderate. </p>
<p>Almindelige (påvirker 1-10 ud af 100 patienter): 
• Hovedpine, søvnighed, forstoppelse, forhøjede værdier ved leverfunktionsprøver, svimmelhed, 
balanceforstyrrelser, kortåndethed, forhøjet blodtryk og overfølsomhed over for medicinen </p>
<p>Ikke almindelige (påvirker 1-10 ud af 1.000 patienter): 
• Træthed, svampeinfektioner, forvirring, hallucinationer, opkastning, unormal gang, hjertesvigt 
og blodprop i en blodåre (vene) </p>
<p>Meget sjældne (påvirker færre end 1 ud af 10.000 patienter): 
• Krampeanfald </p>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data): 
• Betændelse i bugspytkirtlen, leverbetændelse (hepatitis) og psykotiske reaktioner </p>
<p>Alzheimers sygdom er blevet sat i forbindelse med depression, selvmordstanker og selvmord. Disse 
hændelser er blevet beskrevet hos patienter i behandling med Ebixa. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til  Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store ebixa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store ebixa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisteret efter EXP. Udløbsdatoen 
(Exp) er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Ebixa indeholder </p>
<ul>
<li>
<p>Aktivt stof: Memantinhydrochlorid. Hver filmovertrukket tablet indeholder 10 mg 
memantinhydrochlorid svarende til 8,31 mg memantin. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: Mikrokrystallinsk cellulose, croscarmellosenatrium, kolloid vandfri 
silica og magnesiumstearat, som alle findes i tablettens kerne; og hypromellose, macrogol 400, 
titandioxid (E 171) og gul jernoxid (E 172), som alle findes i tablettens overtræk. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Ebixa filmovertrukne tabletter er bleggule til gule, ovale, filmovertrukne tabletter med delekærv og 
præget "1 0" på den ene side og "M M" på den anden side. Tabletten kan deles i to lige store doser. </p>
<p>Ebixa filmovertrukne tabletter fås i blisterpakninger med 14 tabletter, 28 tabletter, 30 tabletter, tabletter, 49 x 1 tabletter, 50 tabletter, 56 tabletter, 56 x 1 tabletter, 70 tabletter, 84 tabletter, tabletter, 98 x 1 tabletter, 100 tabletter, 100 x 1 tabletter, 112 tabletter, 980 (10 x 98) tabletter eller 
1.000 (20 x 50) tabletter. Pakningsstørrelserne 49 x 1, 56 x 1, 98 x 1 og 100 x 1 filmovertrukne 
tabletter findes i unitdose blisterpakninger. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>H. Lundbeck A/S 
Ottiliavej 9 
2500  Valby 
Danmark </p>
<p>Hvis De ønsker yderligere oplysninger om Ebixa, skal De henvende Dem til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen: </p>
<p>Belgique/België/Belgien 
Lundbeck S.A./N.V. 
Tél/Tel: +32 2 535 7 
Lietuva 
H. Lundbeck A/S, Danija 
Tel: + 45 36301 
България 
Lundbeck Export A/S Representative Office 
Tel: +359 2 962 4 
Luxembourg/Luxemburg 
Lundbeck S.A. 
Tél: +32 2 535 7 
Česká republika<br />
Lundbeck Česká republika s.r.o. 
Tel: +420 225 275<br />
Magyarország 
Lundbeck Hungaria Kft. 
Tel: +36 1 4369Danmark 
Lundbeck Pharma A/S 
Tlf: +45 4371 4Malta 
H. Lundbeck A/S, Denmark 
Tel: + 45 36301 
Deutschland 
Lundbeck GmbH 
Tel: +49 40 23649 0 
Nederland 
Lundbeck B.V. 
Tel: +31 20 697 1 
Eesti 
Lundbeck Eesti AS 
Tel: + 372 605 9 
Norge 
H. Lundbeck AS<br />
Tlf: +47 91 300<br />
Ελλάδα 
Lundbeck Hellas S.A. 
Österreich 
Lundbeck Austria GmbH 
Τηλ: +30 210 610 5 
Tel: +43 1 253 621 6 
España 
Lundbeck España S.A. 
Tel: +34 93 494 9Polska 
Lundbeck Poland Sp. z o. o.<br />
Tel.: + 48 22 626 93<br />
France 
Lundbeck SAS 
Tél: + 33 1 79 41 29<br />
Portugal 
Lundbeck Portugal Lda 
Tel: +351 21 00 45<br />
Hrvatska 
Lundbeck Croatia d.o.o. 
Tel.: + 385 1 6448 
România 
Lundbeck Romania SRL 
Tel: +40 21319 88<br />
Ireland 
Lundbeck (Ireland) Limited 
Tel: +353 1 468 9 
Slovenija 
Lundbeck Pharma d.o.o. 
Tel.: +386 2 229 4Ísland 
Vistor hf. 
Tel: +354 535 7 
Slovenská republika 
Lundbeck Slovensko s.r.o. 
Tel: +421 2 5341 42<br />
Italia 
Lundbeck Italia S.p.A. 
Tel: +39 02 677 4 
Suomi/Finland 
Oy H. Lundbeck Ab 
Puh/Tel: +358 2 276 5 
Κύπρος 
Lundbeck Hellas A.E 
Τηλ.: +357 22490 
Sverige 
H. Lundbeck AB 
Tel: +46 4069 98 
Latvija 
H. Lundbeck A/S, Dānija 
Tel: + 45 36301United Kingdom (Northern Ireland) 
Lundbeck (Ireland) Limited 
Tel: +353 1 468 9 </p>
<p>Denne indlægsseddel blev senest ændret MM/ÅÅÅÅ </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p>
<p>Indlægsseddel: Information til brugeren </p>
<p>Ebixa 5 mg/pumpetryk, oral opløsning 
Memantinhydrochlorid </p>
<p>Læs denne indlægsseddel grundigt, inden De begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. </p>
<ul>
<li>Gem indlægssedlen. De kan få brug for at læse den igen. </li>
<li>Spørg lægen eller på apotekspersonalet, hvis der er mere, De vil vide. </li>
<li>Lægen har ordineret Ebixa til Dem personligt. Lad derfor være med at give medicinen til andre. 
Det kan være skadeligt for andre, selvom de har de samme symptomer, som De har. </li>
<li>Kontakt lægen eller apotekspersonalet, hvis en bivirkning bliver værre, eller De får 
bivirkninger, som ikke er nævnt her. Se punkt 4. </li>
</ul>         </div>"""      





                    
Instance: bundlepackageleaflet-en-a0179b039da107bd55842f5819aa0ee7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ebixa Package Leaflet for language en"
Description: "ePI document Bundle for ebixa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a0179b039da107bd55842f5819aa0ee7"
* entry[0].resource = composition-en-a0179b039da107bd55842f5819aa0ee7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa0179b039da107bd55842f5819aa0ee7"
* entry[=].resource = mpa0179b039da107bd55842f5819aa0ee7
                            
                    
Instance: bundlepackageleaflet-da-a0179b039da107bd55842f5819aa0ee7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for ebixa Package Leaflet for language da"
Description: "ePI document Bundle for ebixa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a0179b039da107bd55842f5819aa0ee7"
* entry[0].resource = composition-da-a0179b039da107bd55842f5819aa0ee7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa0179b039da107bd55842f5819aa0ee7"
* entry[=].resource = mpa0179b039da107bd55842f5819aa0ee7
                            
                    



Instance: mpa0179b039da107bd55842f5819aa0ee7
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Ebixa 10 mg film-coated tablets"
Description: "Ebixa 10 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/02/219/001-003"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Ebixa 10 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: a0179b039da107bd55842f5819aa0ee7ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "ebixa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with ebixa"

* subject = Reference(mpa0179b039da107bd55842f5819aa0ee7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#ebixa "ebixa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a0179b039da107bd55842f5819aa0ee7) // ebixa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a0179b039da107bd55842f5819aa0ee7) // ebixa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a0179b039da107bd55842f5819aa0ee7
InstanceOf: List

* insert a0179b039da107bd55842f5819aa0ee7ListRuleset
    